BiotechTube
Cenna Biosciences

Cenna Biosciences

San Diego, United States· Est.
cennabiosciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $26M

Overview

Cenna Biosciences is a preclinical-stage biotech targeting Alzheimer's Disease with its lead peptide drug, Nubytide, which employs a unique mechanism to inhibit Aß production and also addresses inflammation and Tau pathology. The company has secured a strong intellectual property position with multiple issued patents and recently received a $2.7M NIH Phase II SBIR grant to advance Nubytide towards an IND filing targeted for 2025. With a seasoned leadership team and a focus on a large, underserved market, Cenna is positioning itself as a potential disruptor in the AD therapeutic landscape, though it faces significant development and competitive risks inherent to the neurology space.

Alzheimer's Disease

Technology Platform

Proprietary small peptides and molecules designed to inhibit amyloid-beta (Aß) production, with additional effects on neuroinflammation and Tau pathology.

Funding History

1
Total raised:$26M
Series A$26M

Opportunities

The massive and growing global Alzheimer's patient population represents a multi-billion dollar market with urgent unmet need.
Nubytide's profile as a potentially affordable, easily administered, and safer peptide could disrupt the current market dominated by complex monoclonal antibodies, allowing for earlier and broader intervention.
Successful proof-of-concept data could make Cenna a highly attractive acquisition target for large pharma companies seeking to bolster their neurology pipelines.

Risk Factors

The lead program is at a high-risk, preclinical stage in Alzheimer's Disease, a therapeutic area notorious for clinical trial failures.
As a single-asset company, Cenna's entire value is contingent on the success of Nubytide.
The company faces intense competition from well-funded entities developing a wide array of AD therapies, including next-generation antibodies and drugs with different mechanisms of action.

Competitive Landscape

Cenna competes in the crowded Alzheimer's Disease space, directly challenging approved anti-amyloid monoclonal antibodies (e.g., Leqembi from Eisai/Biogen) by positioning Nubytide as a more convenient and potentially safer alternative. It also faces competition from dozens of biopharma companies targeting amyloid, Tau, inflammation, and other pathways across all stages of development. Differentiation will depend on demonstrating a superior efficacy/safety/tolerability profile and ease of use.

More companies in Small Molecule Drugs →More companies in United States →